E_mg_GB_03_vorne-29_3_04

More documents

Recommendations

Info

34 Pharmaceuticals Healthcare – comprising pharmaceuticals, biotechnology and medical technology – is one of the economic growth engines of the 21st century. The reasons for this are growing populations, medical and technological advances, and greater life expectancy. Over the past ten years, spending on medicines in Germany has risen by almost 40 percent to roughly P30 billion. The U.S. pharmaceutical market which, with sales worth the equivalent of roughly P150 billion in 2002, accounted for virtually half of the global market, has almost tripled over this period. And the sector continues to grow disproportionately by eight percent per year worldwide. In 2005, the size of this market is forecast to be at least P390 billion. The biotech industry will also expand strongly over the medium term. More than half of all newly approved drugs now come from the biotech industry. As a value-adding partner to the pharmaceutical industry, GEA and its subsidiaries each occupy leading positions in their respective markets. Niro Pharma Systems is the global market leader in the cutting-edge process engineering used to produce solid medicines. Its technology offering ranges from the batching and weighing of active and inactive ingredients to the granulation and drying stages and the finished tablet. Its customers include almost all major companies in the pharmaceutical industry.
The MODUL tablet press produced by Niro Pharma Systems is not just new – it is revolutionary. Its use drastically cuts the cost of producing tablets. In the past, whenever the product was changed, tablet presses were out of action for between six and ten hours due to the complex cleaning process involved. An innovative compression module, which can be replaced by a clean module within 30 minutes, substantially reduces these downtimes and enables productivity to be raised by up to 50 percent. Roughly 150 million people around the world suffer from the metabolic disorder diabetes. They have to inject themselves with insulin every day. In a few years’ time, a newly developed process should enable patients to inhale insulin. Westfalia Separator’s centrifuges play a key role in the production of insulin. All the world’s leading insulin producers use this firm’s separation technology. 35
Page 1 and 2: “2003 was a year of transition fo
Page 3 and 4: Consolidated Key Figures 2003 RESUL
Page 5 and 6: Creating freedom for action CONTENT
Page 7 and 8: MANAGEMENT SHARE STRATEGY SPECIAL S
Page 25 and 26: zation As the world’s population
Page 33 and 34: The pharmaceutical industry will co
Page 37: Milk Last year, over 160 million co
Page 45 and 46: For a technology-driven organizatio
Page 81 and 82: mg's mission is to ensure sustainab
Page 89 and 90:
MANAGEMENT SHARE STRATEGY SPECIAL S
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
MANAGEMENT AKTIE STRATEGIE SONDERTE
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
Page 183 and 184:
Page 185:
Key Figures for the mg Group RESULT
show all

E_mg_GB_03_vorne-29_3_04

Create successful ePaper yourself

Delete template?

Save as template?